KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherShares Issued
Ratios

Gilead Sciences (GILD) R&D In Process (2019 - 2025)

Gilead Sciences' R&D In Process history spans 7 years, with the latest figure at $80.0 million for Q4 2025.

  • For Q4 2025, R&D In Process rose 827.27% year-over-year to $80.0 million; the TTM value through Dec 2025 reached $564.0 million, down 87.27%, while the annual FY2025 figure was $1.0 billion, 78.04% down from the prior year.
  • R&D In Process reached $80.0 million in Q4 2025 per GILD's latest filing, down from $170.0 million in the prior quarter.
  • In the past five years, R&D In Process ranged from a high of $3.9 billion in Q1 2024 to a low of -$11.0 million in Q4 2024.
  • Average R&D In Process over 5 years is $372.4 million, with a median of $148.0 million recorded in 2021.
  • Peak YoY movement for R&D In Process: skyrocketed 2550.0% in 2023, then tumbled 110.89% in 2024.
  • A 5-year view of R&D In Process shows it stood at $669.0 million in 2021, then crashed by 76.38% to $158.0 million in 2022, then plummeted by 36.08% to $101.0 million in 2023, then crashed by 110.89% to -$11.0 million in 2024, then soared by 827.27% to $80.0 million in 2025.
  • Per Business Quant, the three most recent readings for GILD's R&D In Process are $80.0 million (Q4 2025), $170.0 million (Q3 2025), and $61.0 million (Q2 2025).